Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Frequently asked questions
What sector does Immunovia AB (publ) (IMMVF) operate in?
Immunovia AB (publ) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Immunovia AB (publ) (IMMVF) current stock price?
As of the latest data, Immunovia AB (publ) stock price is $0.01, with a previous close of $0.01.
What is Immunovia AB (publ) (IMMVF) current market capitalization?
Immunovia AB (publ) market cap is approximately 6.73 million.
What is Immunovia AB (publ) (IMMVF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Immunovia AB (publ) (IMMVF) EBITDA?
Immunovia AB (publ) EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.28 million.
Does Immunovia AB (publ) (IMMVF) pay dividends?
No. Immunovia AB (publ) does not pay a dividend.
What is Immunovia AB (publ) (IMMVF) beta (volatility) score?
Immunovia AB (publ) has a beta of 2.636, indicating very high volatility compared to the market.